COMMUNIQUÉS West-GlobeNewswire

Canada House Wellness Group’s Intended Uses of Funds from Recently Closed $8.6 Million Convertible Debenture Unit Financing

22/12/2017 - 15:39

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Canada House Wellness Group Inc. (CSE:CHV) (“ Canada House ” or the “ Company ”) is pleased [...]

Imaging3’s New CEO Provides end-of-year Company Update

22/12/2017 - 15:30

BURBANK, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Imaging3, Inc. (OTCQB:IGNG), a development stage company targeting disruptive technologies in the medical imaging industry, is finishing a transformative 2017 year and [...]

Keryx Biopharmaceuticals to Webcast its Presentation at J.P. Morgan’s 36th Annual Healthcare Conference on January 10, 2018

22/12/2017 - 15:05

BOSTON, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ: KERX ), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced it will [...]

Alpha Pro Tech, Ltd. Announces Additional $2 Million Expansion to Share Repurchase Program

22/12/2017 - 15:00

NOGALES, Ariz., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Alpha Pro Tech, Ltd. (NYSE American:APT), a leading manufacturer of products designed to protect people, products and environments, including disposable protective [...]

GBT Appoints Wendy L. Yarno to Board of Directors

22/12/2017 - 15:00

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT ) today announced the appointment of Wendy L. Yarno to the company’s board of directors. Ms. Yarno has [...]

Eloxx Pharmaceuticals Completes Acquisition Transaction with Sevion Therapeutics

22/12/2017 - 14:37

Company to focus on advancing the clinical development of ELX-02, a disease-modifying therapy for genetic diseases caused by nonsense mutations WALTHAM, Mass., REHOVOT, Israel, and SAN DIEGO, Dec. 22, 2017 (GLOBE [...]

Tauriga Sciences, Inc. Extinguishes its Largest Remaining Balance Sheet Liability for One Time Cash Payment of $15,000 and One Time Issuance of 5,000,000 Restricted Shares; Liability Dated Back to the Years 2010/2011 and Totaled $177,883.71

22/12/2017 - 14:30

NEW YORK, NY, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), engaged in building business through the development, distribution, and licensing of proprietary [...]

Achaogen Announces New Employment Inducement Grants

22/12/2017 - 14:01

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO ), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram- [...]

Portola Pharmaceuticals to Webcast Corporate Update on January 9, 2018

22/12/2017 - 14:00

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA ) today announced that it will host an investor event to discuss expected corporate and product milestones in [...]

Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of peripheral T-cell lymphoma (PTCL)

22/12/2017 - 14:00

La Chaux-de-Fonds, Switzerland, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the active moiety [...]

Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention of Pregnancy

22/12/2017 - 13:30

PRINCETON, N.J., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ: AGRX ), a women’s healthcare company, today announced that the U.S. Food and Drug Administration (FDA) issued a complete response [...]

RedHill Biopharma Announces Initiation of Phase IIa Study with ABC294640 (YELIVA®) for Cholangiocarcinoma at Mayo Clinic and MD Anderson

22/12/2017 - 13:00

YELIVA ® , a proprietary, first-in-class SK2 inhibitor, was granted FDA Orphan Drug designation for the treatment of cholangiocarcinoma Cholangiocarcinoma (bile duct cancer) is a highly lethal malignancy for which there [...]

Avivagen Inc. Announces the Granting of Options

22/12/2017 - 12:30

OTTAWA, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSX-V: VIV ) (OTC Pink:CHEXF) (“ Avivagen ” or the “ Company ”), a life sciences innovation company with a series of patent protected products that support and [...]

Saniona AB: Notice of extraordinary shareholders' meeting in Saniona AB

22/12/2017 - 08:16

PRESS RELEASE December 22, 2017 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail . The shareholders in [...]

Serendipity Ixora proposes distribution of its Xbrane shares to its shareholders, after which Serendipity Group becomes the largest shareholder in Xbrane if the distribution is executed

22/12/2017 - 08:01

Press release 2017-12-22 Xbrane Biopharma AB (publ) ("Xbrane" or "the Company") informs that the Company's largest shareholder Serendipity Ixora AB ("Serendipity Ixora"), intends to distribute all its shares in Xbrane [...]

Xbrane Biopharma largest shareholder Serendipity Group issues a credit facility of SEK 50 million to the company

22/12/2017 - 08:01

Press release 2017-12-22 Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") has today got issued a credit facility from Serendipity Group AB ("Serendipity Group") of SEK 50 million (the "Credit Facility"). The [...]

Saniona AB: The Nomination Committee of Saniona Proposes Election of Two Additional Members of the Board of Directors

22/12/2017 - 08:01

PRESS RELEASE December 22, 2017 Saniona, a leading biotech company in the field of ion channels, today announced that its Nomination Committee comprised of Søren Skjærbæk appointed by Jørgen Drejer, John Haurum [...]

Novartis' combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma

22/12/2017 - 07:16

Priority Review designation based on Phase III study showing 53% reduction in risk of recurrence or death with Tafinlar + Mekinist, as compared to placebo[1] Improvements observed in key secondary endpoints including [...]

Bank of America Merrill Lynch Investment Banking Veteran Joins Hua Medicine as CFO

22/12/2017 - 01:00

SHANGHAI, China, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, announced George Lin, a seasoned investment banker in the U.S. and Asia, joins Hua [...]